Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
22nd Century Group (NASDAQ: XXII) pioneers plant-based solutions for tobacco harm reduction through advanced biotechnology. This news hub provides investors and stakeholders with essential updates on regulatory milestones, product innovations, and operational developments central to the company's mission of reducing nicotine addiction.
Access authoritative coverage of FDA communications, VLN product advancements, and manufacturing capacity updates. Our curated collection includes earnings reports, patent filings, and scientific research collaborations that demonstrate 22nd Century's leadership in developing reduced-nicotine tobacco products.
Key updates feature the company's Modified Risk Tobacco Product authorization, progress in international market expansion, and innovations in nicotine biosynthesis control. Regular updates ensure informed tracking of this biotechnology firm's unique position at the intersection of public health and commercial tobacco production.
Bookmark this page for streamlined access to verified corporate announcements and analysis-free reporting on 22nd Century's progress in redefining tobacco consumption through science-driven solutions.
22nd Century Group (Nasdaq: XXII), a leader in plant-based biotechnology, announced CEO James A. Mish will present at the SNN Network Summer Virtual Event on August 19, 2021, at 2:30 p.m. ET. The event will be accessible via a live webcast on the company’s Investor Relations website. Attendees can request one-on-one meetings with company representatives through the conference website or by contacting investor relations directly. The company focuses on reducing tobacco harm through reduced nicotine content cigarettes and enhancing hemp/cannabis strains for better cannabinoid profiles.
On August 16, 2021, 22nd Century Group (Nasdaq: XXII) celebrated its transfer from the NYSE American to the Nasdaq Capital Market by ringing the Nasdaq Closing Bell. This move reflects the company's strategic growth in the biotechnology sector, focusing on tobacco harm reduction and hemp/cannabis research. CEO James A. Mish indicated the uplisting enhances the company's visibility and supports long-term revenue growth. The common stock will continue trading under the XXII ticker symbol.
22nd Century Group (NYSE American: XXII) announced its common stock uplisting to the Nasdaq Capital Market, effective August 16, 2021. This strategic move aims to enhance visibility to institutional investors and expand exposure to the hemp/cannabis sector as the industry progresses. CEO James A. Mish emphasized the alignment with high-achieving companies, reinforcing their commitment to reducing smoking harm through reduced nicotine tobacco products, and advancing innovations in hemp/cannabis technology.
22nd Century Group (XXII) reported record second quarter net sales of $8.4 million, up over 30% from last year. The company holds a strong cash position of $62.3 million as of June 30, 2021, enhancing its readiness for the upcoming VLN® tobacco product launch and the international expansion planned for early 2022. The FDA's review of the Modified Risk Tobacco Product (MRTP) application is progressing, with no outstanding inquiries. First revenue from its hemp/cannabis franchise is expected in Q3 2021.
22nd Century Group (NYSE American: XXII) has announced a new partnership with a leading tobacco exporter, prompting increased investment in production and testing equipment, as well as staff hiring at its North Carolina facility. The company is positioning itself for the global launch of its VLN® reduced nicotine cigarettes, anticipating FDA authorization soon. Improved testing capabilities are expected to lower production costs significantly. The firm is also seeking to expand its distribution channels.
22nd Century Group, with ticker XXII, announced a live webcast on August 5, 2021, at 10:00 AM ET to discuss its second quarter 2021 results. The company will release its results on the same day at 6:00 AM ET. CEO James A. Mish, COO Michael Zercher, and CFO John Franzino will present the results and discuss growth opportunities in the $1.3 trillion addressable market. An interactive Q&A session will follow. Interested parties can access the webcast via the company’s Investor Relations website. 22nd Century focuses on reducing tobacco harm and advancing hemp/cannabis research.
22nd Century Group (NYSE American: XXII) has established strategic partnerships with leading commercial-scale plant breeders, which will enhance its capabilities in alkaloid-based plant breeding and cultivation. These collaborations are aimed at optimizing development cycles from 7-10 years to just 2 years, crucial for meeting the growing demand for stable hemp/cannabis genetics. The company anticipates monetizing its new plant lines and existing intellectual property in the second half of 2021, signaling multiple revenue streams ahead.
22nd Century Group, Inc. (NYSE American: XXII) has acquired Needle Rock Farms in Colorado, valued at $2.2 million, as part of a restructuring agreement with Panacea Life Sciences. The deal includes exchanging a $7 million note for ownership and a new $4.3 million note secured by Panacea’s operations building, appraised at $10.7 million. Additionally, $7 million in Series B Preferred Stock will be converted into 91 million shares of Exactus, Inc.. This strategic move aims to enhance 22nd Century's cannabis capabilities and generate revenue by the second half of 2021.
22nd Century Group (XXII) reported significant progress under CEO James A. Mish’s leadership in a recent shareholder update. Over the past year, shares have surged by 470%. The company is advancing its Modified Risk Tobacco Product (MRTP) application for the VLN® brand, which could allow for marketing claims of containing '95% Less Nicotine.' Additionally, strategic partnerships in the hemp/cannabis sector and a new Canadian subsidiary are expected to enhance growth. The company aims to capitalize on regulatory changes in tobacco and cannabis markets, with a total addressable market of $1.3 trillion.
22nd Century Group, Inc. (XXII) announced the successful completion of a registered direct offering, selling 10 million shares at $4.00 per share, yielding gross proceeds of $40 million. This capital infusion aims to support various strategic objectives across its plant franchises, including R&D expenses, capital expenditures, and commercialization efforts. The company is positioned to capitalize on recent initiatives in its hemp/cannabis franchise and anticipates continued momentum leading to the launch of its reduced nicotine tobacco product in the near future.
FAQ
What is the current stock price of 22Nd Century (XXII)?
What is the market cap of 22Nd Century (XXII)?
